Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02662569 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 986
- Enrollment target
NCT02662569: Completed Phase 3 study, sponsored by Amgen.
NCT02662569 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 986 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02662569, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 986 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemia.
Interventions
- OTHER Placebo
- DRUG Atorvastatin
- BIOLOGICAL Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 986 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2017-12-06 |
| Phase | Phase 3 |
What the finished NCT02662569 record still lists
NCT02662569 is an interventional study that assigns participants to a tested intervention. The registered 986 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02662569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02662569 about?
NCT02662569 is a clinical study titled "Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia". The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemi...
What is the current status of trial NCT02662569?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 986 participants. The study started on 2016-04-14. Estimated completion is 2017-12-06.
What interventions are being tested in trial NCT02662569?
The interventions under investigation include: Placebo (OTHER), Atorvastatin (DRUG), Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02662569?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02662569's enrollment target sits among peer trials
986 320th of 2000 higher than 1,681 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079841 · 988 participants · Phase 4
The Stimulation To Induce Mothers Study
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI